Stocks News

LAST PRICE
55.8700
TODAY'S CHANGE (%)
Trending Up0.7800 (1.4159%)

Bid / Lots
50.0500/ 1
Ask / Lots
57.5900/ 1
Open / Previous Close
55.0100 / 55.0900
Day Range
Low 54.1500
High 56.5600
52 Week Range
Low 18.7900
High 56.5600
Volume
1,510,459
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 30, 2024
- Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: RVMD
  
  Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
  
  REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
Oct 28, 2024
- DJ Revolution Medicines Is Maintained at Buy by Guggenheim, from 12:49PM ET on Monday Oct 28, 2024 by Dow Jones
  12:49PM ET on Monday Oct 28, 2024 by Dow Jones
  Companies Mentioned: RVMD
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 28, 2024 12:49 ET (16:49 GMT)
- DJ Revolution Medicines Is Maintained at Outperform by Oppenheimer, from 8:58AM ET on Monday Oct 28, 2024 by Dow Jones
  8:58AM ET on Monday Oct 28, 2024 by Dow Jones
  Companies Mentioned: RVMD
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 28, 2024 08:58 ET (12:58 GMT)
- DJ Revolution Medicines Price Target Maintained With a $61.00/Share by Needham, from 8:13AM ET on Monday Oct 28, 2024 by Dow Jones
  8:13AM ET on Monday Oct 28, 2024 by Dow Jones
  Companies Mentioned: RVMD
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 28, 2024 08:13 ET (12:13 GMT)
Oct 25, 2024
- DJ Revolution Medicines Price Target Maintained With a $61.00/Share by Needham, from 4:03PM ET on Friday Oct 25, 2024 by Dow Jones
  4:03PM ET on Friday Oct 25, 2024 by Dow Jones
  Companies Mentioned: RVMD
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 25, 2024 16:03 ET (20:03 GMT)

Today
- DJ This Pharma Stock Is Rising. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo. -- Barrons.com, from 6 hours ago by Dow Jones
  6 hours ago by Dow Jones
  Companies Mentioned: LLY, NVO, VKTX
- DJ Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan, from 6 hours ago by Dow Jones
  6 hours ago by Dow Jones
  Companies Mentioned: ITCI
- Oppenheimer Adjusts Viking Therapeutics Price Target to $164 From $138, Maintains Outperform Rating, from 7 hours ago by MT Newswires
  7 hours ago by MT Newswires
  Companies Mentioned: VKTX
- Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Monday as Investors Focus on Election, Fed Policy Meeting, from 7 hours ago by MT Newswires
  7 hours ago by MT Newswires
  Companies Mentioned: GLD, FAS, FAZ, IBB, IGM, IGV, SOXX, INTC, IVV, IWM, IYE, IYH, IYJ, IYK, IYW, RILY, NVDA, QQQ, SPY, LEU, VDC, VHT, VIS, XLE, XLF, XLI, XLK, XLP, XLV, XLY, YUMC, ATSG, XSD, RTH, USO, SLV, XRT, EXI, BITO, UNG, VKTX, EEM
- Legend Biotech Appoints Alan Bash as President of CARVYKTI(R), from 8 hours ago by Dow Jones
  8 hours ago by Dow Jones
  Companies Mentioned: LEGN
- DJ S&P 500 Futures Climb In Premarket Trading; Talen Energy, Constellation Energy Lag, from 8 hours ago by Dow Jones
  8 hours ago by Dow Jones
  Companies Mentioned: MOS, YUMC, NTR, NTR, CEG, VKTX, TLN, KVYO
- Stocks Gain Pre-Bell Ahead of Presidential Elections, Fed Policy Decision; Asia, Europe Rise, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: ILMN, L, MAR, NVDA, NYT, RVTY, TSLA, NXPI, VRTX, AIG, FOX, FOXA, ZTS, BNTX, BEN, PLTR, CEG, FIS, VKTX, FRPT
- Viking Therapeutics Shares Advance Pre-Bell Amid New 'Positive' Data on VK2735 Studies, from 9 hours ago by MT Newswires
  9 hours ago by MT Newswires
  Companies Mentioned: VKTX
- DJ Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: LLY, NVO, AMGN, VKTX
- Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek(R) 2024, from 9 hours ago by PR Newswire
  9 hours ago by PR Newswire
  Companies Mentioned: VKTX

Revolution Medicines Inc
NASDAQ:RVMDUnited States

Search Criteria

Oct 30, 2024

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones

Oct 28, 2024

DJ Revolution Medicines Is Maintained at Buy by Guggenheim, from 12:49PM ET on Monday Oct 28, 2024 by Dow Jones

DJ Revolution Medicines Is Maintained at Outperform by Oppenheimer, from 8:58AM ET on Monday Oct 28, 2024 by Dow Jones

DJ Revolution Medicines Price Target Maintained With a $61.00/Share by Needham, from 8:13AM ET on Monday Oct 28, 2024 by Dow Jones

Oct 25, 2024

DJ Revolution Medicines Price Target Maintained With a $61.00/Share by Needham, from 4:03PM ET on Friday Oct 25, 2024 by Dow Jones

Peers Headlines

Today

DJ This Pharma Stock Is Rising. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo. -- Barrons.com, from 6 hours ago by Dow Jones

DJ Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan, from 6 hours ago by Dow Jones

Oppenheimer Adjusts Viking Therapeutics Price Target to $164 From $138, Maintains Outperform Rating, from 7 hours ago by MT Newswires

Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Monday as Investors Focus on Election, Fed Policy Meeting, from 7 hours ago by MT Newswires

Legend Biotech Appoints Alan Bash as President of CARVYKTI(R), from 8 hours ago by Dow Jones

DJ S&P 500 Futures Climb In Premarket Trading; Talen Energy, Constellation Energy Lag, from 8 hours ago by Dow Jones

Stocks Gain Pre-Bell Ahead of Presidential Elections, Fed Policy Decision; Asia, Europe Rise, from 8 hours ago by MT Newswires

Viking Therapeutics Shares Advance Pre-Bell Amid New 'Positive' Data on VK2735 Studies, from 9 hours ago by MT Newswires

DJ Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ, from 9 hours ago by Dow Jones

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek(R) 2024, from 9 hours ago by PR Newswire